SCHEMBL24012831

SCHEMBL24012831

CC(C)c1cc(-n2cccn2)ccc1CO

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.41
▸ USP1 O94782 4/20 0.40
▸ LRRK2 Q5S007 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ PDK2 Q15119 1/20 0.38
▸ NLRP3 Q96P20 2/20 0.38
▸ TRPV3 Q8NET8 1/20 0.38
▸ CHRNA7 P36544 1/20 0.37
▸ CHRNA10 Q9GZZ6 1/20 0.37
▸ CHRNA9 Q9UGM1 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22380050 0.79 NOTUM (0.46) NOTUMLRRK2POLBKDM4EALDH1A1
SCHEMBL22380080 0.78 NOTUM (0.42) NOTUMLMNAKDM4EALDH1A1MAPK1
SCHEMBL22214068 0.78 LMNA (0.46) NOTUMLRRK2POLBLMNAKDM4E
SCHEMBL14350243 0.78 CHRM1 (0.47) NOTUMUSP1LMNAKDM4EALDH1A1
SCHEMBL18487985 0.78 NOTUM (0.49) NOTUMUSP1LRRK2POLBKDM4E
SCHEMBL13310516 0.77 PTPN1 (0.43) NOTUMLMNAKDM4EALDH1A1MAPK1
SCHEMBL14350201 0.76 NOTUM (0.46) NOTUMLRRK2POLBKDM4EALDH1A1
SCHEMBL10088508 0.75 PDK2 (0.47) NOTUMLMNAKDM4EALDH1A1MAPK1
SCHEMBL3365354 0.75 NOTUM (0.45) NOTUMLMNAKDM4EALDH1A1MAPK1
SCHEMBL25173729 0.75 NOTUM (0.45) NOTUMLMNAKDM4EALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2023-11-16 — — US disclosed
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2023-11-16 — — US disclosed
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 — — US disclosed
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 — — US disclosed
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2021-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT NOTUM 2836/4885USP1 4051/4885LRRK2 82/4885
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders SMN1; SMN2, SNCA, HTT NOTUM 2836/4885USP1 4051/4885LRRK2 82/4885
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT NOTUM 2836/4885USP1 4051/4885LRRK2 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback